Navigation Links
New guidelines for diagnosing, managing and treating Clostridium difficile
Date:3/21/2010

ARLINGTON, VA (March 22, 2010)A joint panel of experts from the Society for Healthcare Epidemiology (SHEA) and the Infectious Diseases Society of America (IDSA) today released online new clinical practice guidelines for Clostridium difficile infection (CDI) in adults. The guidelines, to be published in the May issue of Infection Control and Hospital Epidemiology, update recommendations regarding the epidemiology, diagnosis, treatment and infection control and environmental management of this disease.

CDI is the most commonly recognized cause of infectious diarrhea in healthcare settings and accounts for 20 percent-30 percent of cases of antibiotic-associated diarrhea. The infection manifests itself in a range from symptomless cases to mild or moderate diarrhea to sudden and sometimes fatal colitis. Since publication of guidelines on CDI in 1995, there has been an increase in overall incidence of the infection, a more virulent strain of the infection has been identified, and evidence regarding the decreased effectiveness of a common treatment of the disease has been reported.

"As healthcare professionals and infectious disease experts, we are committed to developing recommendations based on the best available evidence and practices," said Neil Fishman, MD, president of SHEA. "Since our original guideline was published fifteen years ago, our understanding of the epidemiology of CDI has changed, and requires us to update the way we diagnose and treat this serious infection."

The guidelines provide recommendations on the minimum data that should be collected in cases of CDI and how that data should be reported; the best testing strategy to diagnose CDI; the most important infection control measures for a hospital to implement during an outbreak of CDI; and recommendations on the most appropriate drug treatment for patients with CDI.

"The entire infectious disease community is striving toward making our hospitals and healthcare institutions safer for both patients, families and the healthcare professionals who work in them every day," said Rich Whitley, MD, president of IDSA. "The work of this joint panel of the brightest minds in the field demonstrates how closely and seriously we are studying this infection."

While mortality rates associated with CDI have historically been low, occurring in less than 2 percent of cases, the financial burden to the healthcare system has been significant. From 2000 to 2002, annual excess hospital costs in the U.S. for the management of CDI were estimated at $3.2 billion per year.


'/>"/>

Contact: Tamara Moore
tmoore@gymr.com
202-745-5114
Society for Healthcare Epidemiology of America
Source:Eurekalert

Related biology news :

1. NIH stem cell guidelines should be modified, UCSF team reports
2. Pediatrics GI recommendations -- first step to guidelines for children with autism
3. Health Physics Society recommends considering action for indoor radon below current guidelines
4. LSUHSCs England plays key role in developing new ALS treatment guidelines
5. Journal of Vascular and Interventional Radiology: New patient radiation safety guidelines
6. Following the dietary guidelines may slow heart disease in women
7. New guidelines to fight obesity in pregnancy issued
8. Report updates guidelines on how much weight women should gain during pregnancy
9. First comprehensive guidelines for managing medullary thyroid carcinoma published in Thyroid journal
10. Coral Disease Handbook: Guidelines for Assessment, Monitoring and Management
11. Publication sets guidelines across cancer therapies: Ensuring the best in patient management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
(Date:1/24/2017)... 2017 Biopharm Reports has carried out ... of nuclear magnetic resonance spectroscopy (NMR). This involved ... current practices, developments, trends and end-user plans over ... and opportunities. These areas include growth in the ... and innovation requirements, hyphenated NMR techniques, main suppliers ...
(Date:1/19/2017)... 19, 2017 Sensory Inc ., ... security for consumer electronics, and i ... and cybersecurity solutions, today announced a global partnership ... institutions worldwide to bolster security of data sensitive ... user authentication platforms they offer, innerCore now offers ...
Breaking Biology News(10 mins):
(Date:2/18/2017)... 2017 Research and Markets has announced the ... report to their offering. ... The report provides separate comprehensive analytics for the US, ... Rest of World. Annual estimates and forecasts are provided for the ... for these markets. Market data and analytics are derived from primary ...
(Date:2/17/2017)... Calif. , Feb. 17, 2017  Protagonist ... detailing data on its oral peptide drug candidates, ... Congress of the European Crohn,s and Colitis Organization ... Barcelona, Spain from February ... posters detail preclinical data on Protagonist drug candidates ...
(Date:2/16/2017)... Fla. , Feb. 16, 2017  MDNA ... revolutionizing the development of liquid biopsy tests based ... entered into an exclusive license agreement with its ... MDNA,s proprietary liquid biopsy test for prostate cancer, ... South Korea . This is the first ...
(Date:2/16/2017)... PALM BEACH, Florida , February 16, 2017 ... vastly improving with the infusion of innovative telemedicine ... patient monitoring services that are experiencing a boom ... evolve with the advancement of technologies, services and ... Technologies Inc. (OTC: RQHTF) (TSX-V: RHT), Cellectar Biosciences, ...
Breaking Biology Technology: